Dashboard
Manage Tickers

AMRXAmneal Pharmaceuticals, Inc.

NYSE amneal.com


$ 8.11 $ -0.04 (-0.49 %)    

Tuesday, 20-Aug-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 8.1
$ 8.15
$ 8.10 x 900
-- x --
$ 8.05 - $ 8.20
$ 3.36 - $ 8.28
1,552,995
na
2.6B
$ 0.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-03-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-06-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-05-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-01-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 03-09-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

amneal-announces-fda-approval-for-propofol-injectable-emulsion-single-dose-vials
Amneal Announces FDA Approval For Propofol...
08/20/2024 12:03:54

barclays-maintains-overweight-on-amneal-pharmaceuticals-raises-price-target-to-10
Barclays Maintains Overweight on Amneal Ph...
08/13/2024 12:45:47

Barclays analyst Balaji Prasad maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target ...

truist-securities-maintains-buy-on-amneal-pharmaceuticals-raises-price-target-to-10
Truist Securities Maintains Buy on Amneal ...
08/12/2024 12:50:12

Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target...

amneal-expects-2024-adjusted-eps-of-057-063-versus-prior-guidance-of-053-063-and-consensus-of-061
Amneal Expects 2024 Adjusted EPS Of $0.57-...
08/09/2024 10:10:26

amneal-expects-2024-revenues-of-270b-280b-versus-prior-guidance-of-255b-265b-and-consensus-of-2646b
Amneal Expects 2024 Revenues Of $2.70B-$2....
08/09/2024 10:09:22

Raising Full Year 2024 GuidanceThe Company is raising its previously provided full year 2024 guidance. Updated GuidancePrior Gu...

amneal-pharmaceuticals-q2-2024-adj-eps-016-beats-014-estimate-sales-701780m-beat-658140m-estimate
Amneal Pharmaceuticals Q2 2024 Adj. EPS $0...
08/09/2024 10:07:13

amneal-receives-fda-approval-for-ipx203-for-parkinsons-disease-to-be-launched-as-crexont-extended-release-capsules
Amneal Receives FDA Approval for IPX203 Fo...
08/07/2024 21:20:48

Delivers more "Good On" time with less frequent dosing compared to Immediate Release CD/LDUnderscores Amneal's lead...

amneal-pharmaceuticals-receives-fda-approval-for-new-potassium-phosphates-iv-infusion-bag-first-preservative-free-single-dose-presentation-third-505b2-injectable-added-this-year-launching-in-q3
Amneal Pharmaceuticals Receives FDA Approv...
07/29/2024 20:25:58

amneal-pharmaceuticals-launches-focinvez-ready-to-use-injectable-anti-nausea-agent-for-chemotherapy-second-injectable-rtu-product-launched-in-2024-single-dose-vial-free-of-polysorbate-80-no-reconstitution-required
Amneal Pharmaceuticals Launches Focinvez, ...
07/09/2024 20:24:17

kashiv-biosciences-enters-into-exclusive-licensing-agreement-with-amneal-for-commercialization-of-a-proposed-biosimilar-to-xolair
Kashiv BioSciences Enters Into Exclusive L...
07/01/2024 12:02:59

Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO® & FYLNETRA®)ADL018 is Kashiv's lead p...

Core News & Articles
Reported Monday June 10, 2024 "Amneal, U.S...
06/11/2024 14:40:07

https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/ Drugmaker A...

amneal-expands-broad-injectables-portfolio-with-the-addition-of-six-new-product-launches
Amneal Expands Broad Injectables Portfolio...
06/05/2024 12:14:13

Amneal's Q2 2024 injectable product launches: Product launchDosage formASHP drug shortage1PEMRYDI RTU®VialNo2Atropine sulfa...

amneal-has-begun-supplying-otc-naloxone-hydrochloride-nasal-spray-to-us-retail-pharmacies-and-the-state-of-california
Amneal Has Begun Supplying OTC Naloxone Hy...
05/22/2024 20:32:47

Significantly expanding access to affordable, life-saving opioid overdose rescue medicineEntered distribution agreement with Ca...

assessing-amneal-pharmaceuticals-insights-from-4-financial-analysts
Assessing Amneal Pharmaceuticals: Insights...
05/06/2024 19:00:55

goldman-sachs-maintains-buy-on-amneal-pharmaceuticals-raises-price-target-to-8
Goldman Sachs Maintains Buy on Amneal Phar...
05/06/2024 15:15:42

Goldman Sachs analyst Nathan Rich maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from...

truist-securities-reiterates-buy-on-amneal-pharmaceuticals-raises-price-target-to-9
Truist Securities Reiterates Buy on Amneal...
05/06/2024 12:32:09

Truist Securities analyst Les Sulewski reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price targe...

generic-drugmaker-amneal-announces-over-270m-in-us-opioid-lawsuit-settlement
Generic Drugmaker Amneal Announces Over $2...
05/03/2024 18:43:45

Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 ear...

correction-amneal-reaffirms-2024-revenue-guidance-of-255b-265b-versus-consensus-of-260b-with-adjusted-eps-of-053-063-compared-to-guidance-of-058
CORRECTION: Amneal Reaffirms 2024 Revenue ...
05/03/2024 18:09:08

amneal-pharmaceuticals-q1-2024-adj-eps-014-beats-009-estimate-sales-659191m-beat-619033m-estimate
Amneal Pharmaceuticals Q1 2024 Adj EPS $0....
05/03/2024 10:04:17

Amneal Pharmaceuticals (NYSE:AMRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of ...

amneal-announces-fda-approval-of-over-the-counter-naloxone-hydrochloride-nasal-spray-for-emergency-treatment-of-opioid-overdose
Amneal Announces FDA Approval Of Over-The-...
04/24/2024 12:12:36

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION